Skip to content


  • Poster presentation
  • Open Access

Early hematopoietic stem cell transplantation improve treatment outcome of aggressive ATL.

  • 1Email author,
  • 1,
  • 2,
  • 3,
  • 4,
  • 4 and
  • 1, 2
Retrovirology201512 (Suppl 1) :P28

  • Published:


  • Lymphoma
  • Overall Survival
  • Median Time
  • Hematopoietic Stem Cell Transplantation
  • Induction Chemotherapy

Aggressive ATL is one of the most intractable peripheral T cell malignancies and outcome of chemotherapy is still unsatisfactory. Hematopoietic stem cell transplantation (HSCT) is a promising strategy to improve treatment results of aggressive ATL but the proportion of the ATL patients who received HSCT in the potential candidates is low. In this study we treated 45 consecutive aggressive ATL patients with intensive combination chemotherapies (mainly mLSG15) followed by HSCT if indicated. We started to search HSC donor as soon as possible after starting chemotherapy in order to advance HSCT. In a total of 45 patients, 39 were acute type, 4 were lymphoma type, and 2 were unfavorable chronic type. The median age of the patients was 59 years (range 28-68). Thirty-one patients finally received allo-HSCT (related BMT/PBSCT 5, unrelated BMT 26). The proportion of the patients who received HSCT was 68.9%. Disease status at transplantation was CR in 2, PR in 17, SD in 7 and PD in 4 patients. Median time to HSCT from beginning of chemotherapy was 166 days. Three-year overall survival (OS) of the all patients receiving HSCT and those who receive HSCT in CR/PR were 60.0% and 76.5% respectively. Three-year OS of total 45 patients was 41.5%. Among 13 patients who could not receive HSCT, 6 relapsed after initial response to chemotherapy (median time to relapse from the beginning of chemotherapy was130 days) and 2 were in primary refractory state, which were the reason they could not receive HSCT. Those 6 relapsed patients might receive HSCT if they could find suitable HSC donor earlier. Our study suggest that early surveillance of HSCT donor along with remission induction chemotherapy raise up the proportion of patients receiving HSCT and improve treatment results in aggressive ATL.

Authors’ Affiliations

Department of Hematology/Oncology, Research Hospital, Institute of Medical Science, the University of Tokyo, Tokyo, Japan
Department of Molecular Therapy, Institute of Medical Science, the University of Tokyo, Tokyo, Japan
Department of Blood Transfusion and Cellular Therapy, National Cancer Center Hospital, Tokyo, Japan
Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan


© Uchimaru et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.